Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents

February 5, 2018

Responsive image

AUSTIN, Texas, Feb. 5, 2018 /PRNewswire/ — Vermillion, Inc. (NASDAQ: VRML) announced today that it has been granted two new US patents that significantly expand coverage for its core technologies, OVA1™ and Overa™.

The first, US Patent No. 9,816,995, entitled “Biomarker for…

Category: Precious Metals